A Phase 1 Study of Cizutamig in IgE Mediated Diseases
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-65
SponsorCandid Therapeutics
About this trial
The purpose of this study is to evaluate the pharmacodynamics, safety, tolerability, pharmacokinetics, and immunogenicity of cizutamig in IgE Mediated Diseases.
Eligibility criteria
Qualifiers
History of documented (skin prick test, in vitro testing, or food challenge), ongoing, IgE-mediated allergy to food (eg, peanut, hazelnut, walnut, cashew, milk, egg/egg white, soy, wheat, sesame, cod, salmon, tuna, lobster, crab and/or shrimp) with Screening total IgE ≥ 400 IU/mL
Diagnosis of chronic rhinosinusitis with Screening total IgE > ULN
Diagnosis of allergic rhinitis with Screening total IgE > ULN
Diagnosis of asthma and classified as well controlled per 2024 Global Initiative for Asthma guidelines with Screening total IgE > ULN
Disqualifiers
Elevated IgE levels for reasons other than the IgE mediated diseases
Planned ingestion of food items to which they are allergic for the duration of the study (for food allergy patients)
Current use of any allergen immunotherapy.
Individuals whose allergen exposures in their home and/or work environments may be expected to change significantly during the trial period
Trial design
Treatments tested in this trial
- Cizutamig
Treatment groups
20 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov